Risk factor
Poor trading liquidity
Profitability factor
Very poor margins and returns
About
Thonburi Healthcare Group Public Company Limited, alongside its affiliated entities, manages private hospitals throughout Thailand. The company's operations are divided into three primary segments: Medical Services, Healthcare Solution Provision, and Other Businesses. It offers a comprehensive range of medical treatments, encompassing specialized care in neurosciences, orthopedics, gastroenterology, cardiology, and obstetrics and gynecology. Additionally, the group provides management expertise for provincial government hospitals and heart centers across both public and private sectors. Its varied business interests also include offering elder care and senior living facilities, in-home healthcare services, and operating patient rehabilitation centers. Furthermore, the company engages in real estate development for senior housing, oversees elderly care facilities, and distributes a wide array of dental supply brands such as Adec, W&H, AO, Heraeus, Ivoclar, Megagen, SAM, Melag, and Alpro. Other ventures involve the retail sale of pharmaceuticals and medical supplies in specialized outlets, the creation of hospital management software, and broader property development. Thonburi Healthcare Group operates a network of hospitals that includes four facilities in or near Bangkok (Thonburi, Thonburi 2, Thonburi Bamrungmuang, and Thonburi Burana Hospital in Pathum Thani), four provincial hospitals (Rajyindee, Ubonrak Thonburi, Sirivej Chanthaburi, and Thonburi Thungsong), and one international hospital located in the Republic of the Union of Myanmar. Founded in 1976, the company maintains its headquarters in Bangkok, Thailand.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, 'cheap' on EV/EBITDA, tra
Target Price
The average target price of THG.BK is 8.6 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation